ArticleMedical oncology (Northwood, London, England)2013
Prognostic significance of serum miR-17-5p in lung cancer.
Article in Medical oncology (Northwood, London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- MicroRNA-17 and the prognosis of human carcinomas: a systematic review and meta-analysis.BMJ open · 2018Pooled it
- Prognostic value of high-expression of miR-17-92 cluster in various tumors: evidence from a meta-analysis.Scientific reports · 2017Pooled it
- Diagnostic value of PPARδ and miRNA-17 expression levels in patients with non-small cell lung cancer.Scientific reports · 2021Trial
- miR-17-5p is highly expressed in patients with lung cancer and promoted lung cancer by targeting SIK1.Discover oncology · 2025Article
- The Pleiotropic Role of the MicroRNA-17-92 Cluster in Cardiovascular Diseases and Cancer.Reviews in cardiovascular medicine · 2025Review
- Prognostic impact of miR-17-5p and miR-20a-5p in NSCLC diverge in subgroups according to lymph node status.Frontiers in oncology · 2025Article
- Changes in Circulating MicroRNA Levels as Potential Indicators of Training Adaptation in Professional Volleyball Players.International journal of molecular sciences · 2024Article
- Identifying the roles of miR-17 in ciliogenesis and cell cycle.Frontiers in cell and developmental biology · 2024Article
- Circulating exosomal miRNAs as a promising diagnostic biomarker in cancer.Physiological research · 2023Review
- Post-prostatic-massage urine exosomes of men with chronic prostatitis/chronic pelvic pain syndrome carry prostate-cancer-typical microRNAs and activate proto-oncogenes.Molecular oncology · 2023Article
- Review
- Article
- MiRNAs in Lung Cancer: Diagnostic, Prognostic, and Therapeutic Potential.Diagnostics (Basel, Switzerland) · 2022Review
- Overexpression of miR-17 predicts adverse prognosis and disease recurrence for acute myeloid leukemia.International journal of clinical oncology · 2022Article
- Spectrum of microRNAs and their target genes in cancer: intervention in diagnosis and therapy.Molecular biology reports · 2022Review
- Article
- New biomarkers in peripheral blood of patients with ovarian cancer: high expression levels of miR-16-5p, miR-17-5p, and miR-638.Archives of gynecology and obstetrics · 2022Article
- BTN3A2 Expression Is Connected With Favorable Prognosis and High Infiltrating Immune in Lung Adenocarcinoma.Frontiers in genetics · 2022Article
- microRNA-based diagnostic and therapeutic applications in cancer medicine.Wiley interdisciplinary reviews. RNA · 2021Review
- Cucurbitacin B enhances apoptosis in gefitinib resistant non‑small cell lung cancer by modulating the miR‑17‑5p/STAT3 axis.Molecular medicine reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
miR-17-5p is abnormally expressed in various tumor types. The aim of this study was to investigate the expression level of miR-17-5p in serum of patients with lung cancer and to determine whether serum miR-17-5p expression is related to the prognosis of patients with lung cancer. RT-qPCR was used to examine expression of miRNA-17-5p in 20 pairs of lung cancer and adjacent normal tissues, and sera from 221 patients with lung cancer and 54 matched controls. The correlation of serum miR-17-5p with clinicopathological factors or prognosis of patients with lung cancer was analyzed. The expression level of miR-17-5p obviously increased in lung cancer tissues (P = 0.004). Furthermore, serum miR-17-5p expression also significantly increased in patients with lung cancer compared with healthy individuals (P = 0.03). The survival analysis showed that serum miR-17-5p expression was closely related to the survival of patients with lung cancer. Patients with high miR-17-5p expression had shorter survival times [hazard ratio (HR) = 1.767, 95 %CI 1.039-3.005, P = 0.035]. A lower expression level of serum miR-17-5p helps extend the survival of patients with lung cancer. Thus, miR-17-5p may be potential biomarker for prediction the prognosis in patients with lung cancer.
Indexed as
Identifiers
23263848What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.